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5Background: Utilities are often a main outcome parameter in eco-
nomic evaluations. Because depression has a large influence on quality
of life, it is expected that utilities are responsive to changes in
depression. Objective: To evaluate the change in utility derived from
different instruments in depression, including the Short Form 6D (SF-
6D), the Euroqol based on the UK (EQ-5DUK), the Euroqol based on the
utch tariff (EQ-5DNL), and utilities derived from Beck Depression In-
ventory Second Edition (BDI-II) using theDepression-Free-Daymethod.
Method: This study evaluated the responsiveness, the minimally im-
portant difference, and the agreement in utility change derived from
the different instruments. Results: The SF-6D, EQ-5DUK, and EQ-5DNL
were responsive. Theminimally important difference values are in line
with previous studies, about 0.3. The Depression-Free-Day method
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doi:10.1016/j.jval.2010.12.004early always resulted in positive utility changes, even for subgroups
hat had no change or deterioration in health status or depression.
herewas poor agreement between utility changes of the SF-6D, EQ-5D
either EQ-5DUK or EQ-5DNL), and DFDu. Conclusions: The SF-6D, EQ-
DUK, and EQ-5DNL seem responsive and thus adequate for estimating
utility in depression treatment. We do not recommend the use of the
Depression-Fee-Day method. The low agreement between utility
changes indicates that outcomes of the different instruments are in-
comparable.
Keywords: depression, depression-free-day, EQ-5D, quality of life
utility, SF-6D, validity.
Copyright © 2011, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Measuring health-related quality of life is relevant in patientswith
depression because depression has a large influence on the phys-
ical, social, and emotional aspects of a patient’s well-being [1,2]. In
he field of economic evaluation, generic health-related quality of
ife (e.g., Euroqol [EQ-5D], Short Form6D [SF-6D]) is often one of the
ain outcome parameters. These instruments express health-
elated quality of life in utilities, which theoretically can range
rom zero (the worst imaginable condition: death) to one (perfect
ealth). Utilities are mainly used in economic evaluation and
ealth technology assessment. These fields of study are to help
olicymakers in resource allocation decisions [3]. Therefore, it
s important that these utilities are responsive to changes in
ealth status. However, in our randomized trial comparing
hree depression treatments, we found improvement in depres-
ion, but no improvement in utilities measured by the EQ-5D
nd SF-6D [4]. This raises questions on the responsiveness of
hese measures for use in depression studies. As suggested by
cCrone et al. [5] and others [6], a likely limitation of the exist-
* Address correspondence to: Sylvia A. H. Gerhards, Department
6200 MD Maastricht, The Netherlands.
E-mail: S.Gerhards@maastrichtuniversity.nl.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.ng utility measures might be their large focus on physical
ealth.
Asmentioned, depression affects several domains of quality of
ife, and consequently the utility measures should be responsive
o changes in depression. Another aspect besides responsiveness
s the question what utility change constitutes a relevant change.
alculation of the minimally important difference (MID) in utility
hange might be helpful here. The MID has been defined as “the
mallest difference in score in the domain of interest that patients
erceive as important, either beneficial or harmful, and which
ould lead the clinician to consider a change in the patient’sman-
gement” [7].
This study evaluates change in utility during a 12-month fol-
ow-up period for patients with depression complaints. Utilities
re calculated using the EQ-5D and SF-6D questionnaires, but also
erived from depression severity questionnaires such as the Beck
epression Inventory Second Edition (BDI-II), using the Depres-
ion-Free-Day (DFD) method [8,9]. Because several cost-effective-
ess studies of depression treatments have used this approach to
erive health-related quality of life from the BDI-II [10–12] or other
inical Psychological Science, Maastricht University, P.O. Box 616,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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733V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 3 2 – 7 3 9depression questionnaires [13–21], this study included the DFD-
erived utility (DFDu). Although the DFD method might give sim-
lar cost-utility ratios as generic instruments, recent studies have
hown that these DFD-based quality-adjusted life years (QALYs)
re significantly higher [8] and have a poor tomoderate agreement
ith QALYs derived from the SF-6D and EQ-5D [22]. Therefore, this
tudy will evaluate the responsiveness, the MID, and the agree-
ent in utility change derived from the EQ-5D, SF-6D, as well as
he DFDu. We followed the recommendations of Revicki et al. [23]
o assess the responsiveness, which implies 1) selecting an anchor
o define change in health status; 2) classifying patients accord-
ngly into subgroups; and 3) examining responsiveness by means
f statistical indicators.
Method
Design and participants
Data are used froma randomized trial comparing: 1) computerized
cognitive behavioral therapy (CCBT); with 2) treatment as usual by
a general practitioner (TAU); and 3) a combination of both CCBT
and TAU for people with depressive complaints (BDI-II score 16;
ge 18–65). In the trial, 303 participants were recruited from the
eneral population in the south of the Netherlands by means of a
arge-scale Internet-based screening. During a 1-year follow-up
eriod, participants were asked to fill in Internet questionnaires.
urther details of the design of the trial, the interventions, and the
opulation can be found elsewhere [24,25].
Depression severity
Depression severity was measured with the BDI-II. The total score
is the sum of the 21 items with a range of 0 (no depression) to 63
(severe depression). There has been consistent support for the
construct validity and reliability of the BDI-II in various samples
[26–28]. For patients diagnosed with depression a BDI-II score of 0
to 13 is categorized “minimal,” 14 to 19 “mild,” 20 to 28 “moderate
severe,” and 29 to 63 “severe” depression [28].
Utility instruments
Utilities were derived from the EQ-5D and the SF-6D. A utility
refers to the preference that individuals or society have for any
particular set of health outcomes [3]. The EQ-5D consists of five
health state dimensions (i.e., mobility, self-care, usual activity,
pain/discomfort, and anxiety/depression) on which the respon-
dent has to indicate his own health status choosing from three
levels (no problem, some problems, and major problems)
[29,30]. Standardized value sets are available to calculate the
utility based on the EQ-5D. This study used the UK tariff (EQ-
5DUK) and the Dutch tariff (EQ-5DNL) [31,32].
The SF-6D is a utility instrument based on the health-related
uality of life questionnaire 36-item short-formHealth Survey (SF-
6). The utility is derived from 11 items of the SF-36 and is com-
osed of six dimensions of health (i.e., physical functioning, role
imitations, social functioning, pain, mental health, and vitality).
he SF-6D utilities were derived bymeans of the preference-based
K tariff [33,34], no Dutch tariff is available.
Although theoretically a utility ranges from 0 (the worst
maginable condition: death) to 1 (perfect health), the EQ-5DUK
results in a range from 0.59 to 1, EQ-5DNL results in a range
rom 0.33 to 1, and the SF-6D tariff results in a range from 0.30
o 1.
DFDu
The DFD method was originally developed by Lave et al. [9]. By
eans of this method, disease-specific symptom severity infor-mation from the BDI-II and the Hamilton Rating Scale-Depression
is converted into DFDs and subsequently transformed into a util-
ity-weighted score to estimate QALYs [8,9]. Because we only had
data on the BDI-II, we derived the DFD from the BDI-II outcomes.
TheDFD attaches utilityweights in a range of 0.6 to 1.0 at the BDI-II
outcome. For all BDI-II scores below 9, the derived utility is 1.0
because the person is considered not depressed. For all BDI-II
scores above 21, the derived utility is 0.6 because this person is
considered depressed. The derived utility for BDI-II scores be-
tween 9 and 21 are calculated proportionally [8].
Analysis
All available data of the baseline and 12-month follow-up period
were used. Data of patients lost to follow-up were not imputed.
Change scores in utility from baseline to 12month follow-up were
calculated. The normality of the data was assessed by means of
histograms and skewness and kurtosis statistics. All analyses
were carried out using SPSS version 15.0.1 for Windows (SPSS Inc,
Chicago, IL).
Anchor-based subgroups
To evaluate the responsiveness of the SF-6D, EQ-5DUK, EQ-5DNL,
and DFDu utilities, we followed the anchor-based approach ac-
cording to the recommendations of Revicki et al. [23]. In this ap-
proach, the population is divided into several subgroups based
on certain criteria. These criteria—or anchors—indicate if pa-
tients have improved or worsened over time. The anchors are
external indicators; for example, clinical end points or patient-
based ratings of change can be used as an anchor. Because it is
recommended to use multiple independent anchors to confirm
responsiveness [23], we used two BDI-II-based anchors and one
retrospective self-report anchor.
For the BDI-II-based anchor, we used the methodology of Ja-
cobson and Truax [35,36] to determine clinically meaningful
changes on the BDI-II. This approach is based on two components:
1) reliable change (RC), being the extent to which the pre- to post-
difference score is reliable taking into account the measurement
variability of the instrument, and 2) clinically significant change
(CSC), being the extent to which posttreatment scores are clini-
cally meaningful. In our population, the RC was calculated as a
change of at least nine points during follow-up, and the CSC as a
follow-up score below 12 on the BDI-II [24]. Based on the RC, the
following three subgroups were created: deterioration (i.e., deteri-
oration by at least nine points on the BDI-II), no change, and im-
provement (i.e., an improvement with at least nine points on the
BDI-II). Based on the CSC, the population was divided in two sub-
groups: improvement and no improvement (i.e., still depressed a
BDI-II score  12).
For retrospective self-report, the SF-36 health change itemwas
used as an anchor. This item is a global rating of change (GRoC)
scale and consists of the question “Compared to 1 year ago, how
would you rate your health in general now?” The population is
divided into five subgroups, based on the answers given on a five-
point Likert scale (5Much better now, 4 Somewhat better now,
3 About the same, 2 Somewhat worse, 1Much worse than 1
year ago). The GRoC item is not included in the SF-6D.
As recommended by Revicki et al. [23], the correlation between
the anchor and the change in utility (i.e., SF-6D, EQ-5DUK, EQ-5DNL,
and DFDu) was assessed. A correlation of 0.30 to 0.35 was used as
a threshold to define an acceptable association [23]. Due to non-
normality of the data, the Spearman correlation was used.
MID
The MID in utility change was calculated according to the anchor-
based approach. The GRoC was used as anchor, assuming that
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734 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 3 2 – 7 3 9patientswith a score of four or two have experienced some change
equivalent to the MID [37,38]. The MID was calculated separately
for respondents who rated their health to be somewhat better
(Item 4) and respondents who rated their health somewhat worse
(Item 2) than 1 year ago.
Responsiveness
In a scatterplot the change in BDI-II was related to the change in
utility. Responsiveness to change was based on statistical indica-
tors, being the standardized response mean (SRM) and the effect
size (ES) [23,39]. The method to calculate the SRM was SRM 
Mfollow-up Mbaseline/SDChange, where Mbaseline is the mean score at
aseline, Mfollow-up is the mean score at the follow-up moment,
nd SDChange is the standard deviation of the change in score [40].
The method to calculate ES was ES  Mfollow-up  Mbaseline/SDbase-
ine, where Mbaseline is the mean score at baseline, Mfollow-up is the
ean score at the follow-up moment, and SDbaseline is the pooled
tandard deviation at baseline [41]. The interpretation of the SRM
nd ES is based on Cohen’s guidelines, where a score less than 0.20
s considered trivial, from 0.20 to less than 0.50 is considered
mall, from 0.50 to less than 0.80 is considered medium, and from
.80 and greater is considered a large change score [41].
Agreement between utility changes
To study the agreement between the different measures’ utility
changes from baseline to 12 month follow-up, Spearman correla-
tions and intraclass coefficients (ICC) were calculated. A two-way
mixed effect model was used to calculate the ICC for full agree-
ment [42]. An ICC below 0.40 implies poor reliability, between 0.40
and 0.75moderate reliability, and above 0.75 indicates good agree-
ment [43,44].
Table 1 – Baseline characteristics of participants (n = 267).
Characteristic Descriptive statistic
Sex, male, n (%) 118 (44%)
Age, M (SD) 45.0 (11.5)
Educational level*
Low, n (%) 48 (19%)
Middle, n (%) 140 (54%)
High, n (%) 72 (28%)
Partner, yes, n (%)† 187 (72%)
Employed, yes, n (%)‡ 174 (65%)
M, mean; SD, standard deviation.
* Data unavailable for 7 persons.
† Data unavailable for 7 persons.
‡ Data unavailable for 28 persons.
Table 2 – Baseline scores (T0), 12-month scores (T1), chang
size (ES) of depression severity and utilities of the total sam
Characteristic T0 T1
BDI-II, M (SD) 27.66 (7.65) 17.21 (11.
SF-6D, M (SD) 0.66 (0.08) 0.68 (0.1
EQ-5DUK, M (SD) 0.71 (0.20) 0.70 (0.2
EQ-5DNL, M (SD) 0.71 (0.18) 0.72 (0.2
DFDu, M (SD) 0.62 (0.05) 0.78 (0.1
BDI-II, Beck Depression Inventory, Second Edition; SF-6D, Short-Form
the UK tariff; EQ-5DNL, Euroqol 5D utility derived by the Dutch tar
M, mean; SD, standard deviation.Results
Population
In total, data of 267 trial participants were available at 12 month
follow-up. Table 1 presents the baseline characteristics of these
participants. Table 2 presents the baseline scores, 12-month follow-
up scores, change scores, SRM and ES of the BDI-II, and utilities of
the complete sample. As shown by the SRM and ES, there are no
improvements in EQ-5DUK and EQ-5DNL, only small improvements
in SF-6D, and large improvements in BDI-II and DFDu.
Anchor-based subgroups
According to the recommendations of Revicki et al. [23], a correla-
tion of at least 0.30 to 0.35 between the anchor and the change in
utility was required to use the anchor as a threshold. As presented
in Table 3, the association between the anchors and the utility
hange scores from baseline to 12 months was of an acceptable
evel, with all three anchors showing significant medium correla-
ions in the range of 0.309 to 0.472, except for the high correlations
f 0.722 and 0.793 between the DFDu and the RC and CSC anchor.
Responsiveness
The scatterplots of Figure 1 indicate that for each of the utility
instruments a large number of respondents showed no change
(i.e., SF-6D, EQ-5DUK, EQ-5DNL and DFDu change of 0.00). However,
there seems to be a trend that an improvement in utility change is
associated with an improvement of depression symptoms mea-
sured by the BDI-II. The SF-6D, EQ-5DUK, EQ-5DNL, and DFDu utili-
res (), standardized response mean (SRM), and effect
(n = 267).
 SRM ES
10.44 (11.02) 0.95 1.37
0.02 (0.09) 0.21 0.24
0.005 (0.26) 0.02 0.02
0.01 (0.25) 0.06 0.08
0.16 (0.16) 1.01 3.56
tility derived by the UK tariff; EQ-5DUK, Euroqol 5D utility derived by
FDu, Depression-Free-Days derived utility derived from the BDI-II;
Table 3 – Spearman correlations between anchors and
utility change from baseline to 12-months follow-up
(n = 267).
Utility change Anchor
RC CSC GRoC
SF-6D 0.368 0.334 0.437
EQ-5DUK 0.355 0.309 0.386
EQ-5DNL 0.398 0.330 0.379
DFDu 0.722 0.793 0.472
All correlations are significant at the 0.01 level.
SF-6D, Short-Form 6D utility derived by the UK tariff; EQ-5DUK, Eu-
roqol 5D utility derived by the UK tariff; EQ-5DNL, Euroqol 5D utility
derived by the Dutch tariff; DFDu, Depression-Free-Days derived
utility derived from the BDI-II; RC, reliable change on the BDI-II (i.e.,
a decrease of at least 9 points during follow-up); CSC, clinically
significant change on the BDI-II (i.e., a follow-up score below 12);
GRoC, global rating of change.e sco
ple
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735V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 3 2 – 7 3 9ties at baseline and 12 months follow-up, their change scores,
SRM, and ES are presented in Table 4.
DFDu
Regarding the DFDu, the direction of the SRM and ES did not always
correspondwith thedirectionof changeaccording to theanchor. The
DFDu showed medium to large positive SRM and ES for all anchor
subgroups (i.e., improvement, no change, and deterioration), with
only exception of the RC subgroup with deterioration.
SF-6D, EQ-5DUK, and EQ-5DNL
For the RC anchor, all three genericmeasures SF-6D, EQ-5DUK, and
EQ-5DNL showed large SRM and ES for the deterioration subgroup,
and small to medium changes for the improvement subgroup. In
the RC subgroupwithout reliable change, the SRMand ES did show
small negative changes for the EQ-5DUK and EQ-5DNL.
In the CSC improvement subgroup, the SRM and ES showed
Fig. 1 – Scatterplots of the change in depression severity rela
up (n = 267). BDI-II, Beck Depression Inventory, 2nd edition;
uroqol 5D utility derived by the UK tariff; EQ-5DNL, Euroqol
ays derived utility derived from the BDI-II. For interpretatio
alculated such that positive change scores reflect an impro
n health status.mall to large improvements on all three utility measures. For the Eubgroup without improvement, the SRM and ES of the SF-6D and
Q-5DNL and the SRM of the EQ-5DUK did not show substantial
changes in utility. The ES of the EQ-5DUK, showed a small decrease
n utility.
For the GRoC anchor, the subgroups with large deterioration/im-
rovement showed medium to large SRM and ES on all utility mea-
ures. For the no change GRoC subgroup, there were no substantial
hanges in utility foundonall SRMandES outcomes. Although small
mprovements on the GRoC were related with SRM and ES showing
mall improvements in SF-6D and EQ-5DNL, no substantial improve-
ents were detected for the EQ-5DUK changes. Conversely, the
Q-5DUK SRMand ES showed small utility changes for the GRoC sub-
group with small deterioration, whereas no substantial changes
were detected in SF-6D and EQ-5DNL.
Comparing these three instruments, the SRM and ES of im-
rovement subgroups were highest for the SF-6D, and lowest for
Q-5D ,whereas all three utilitymeasures showed large SRMand
to the change in utility from baseline to 12-month follow-
D, Short-Form 6D utility derived by the UK tariff; EQ-5DUK,
tility derived by the Dutch tariff; DFDu, Depression-Free-
the scatterplots: Both BDI-II and utility changes were
ent, whereas negative change scores reflect a deteriorationted
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5D u
n of
vemUK
S values for (large) deterioration subgroups. The standard devia-
E
S
t
r
b
v
0
5
c
t
736 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 3 2 – 7 3 9tions of the baseline utility and the utility change from baseline to
follow-upwere lower for the SF-6D as opposed to the EQ-5DUK and
Q-5DNL, which can explain the larger SRM and ES values of the
F-6D.
MID
The MID based on the GRoC can be read from Table 4 as being
0.01, 0.05, and 0.03 for SD-6D, EQ-5DUK, and EQ-5DNL, respec-
ively, in the small deterioration subgroup, and 0.03, 0.03, and 0.04,
espectively, in the small improvement subgroup.
Agreement between utility changes
Table 5 presents the correlations and ICCs of the utility changes
derived from the different instruments used in this study. All cor-
relations and ICCs were significant. Correlations with the DFDu
Table 4 – Baseline scores (T0), 12-month scores (T1), chang
response mean (SRM), and effect size (ES) of utility per sub
Anchor subgroup SF-6D EQ-5DUK
T0 T1 (SD) SRM ES T0 T1 (SD)
RC
Deterioration
(n  8)
0.58 0.49 0.09 (0.05) 1.65 1.09 0.63 0.13 0.50 (0.40)
No change
(n  117)
0.65 0.64 0.01 (0.07) 0.19 0.15 0.70 0.64 0.07 (0.24)
Improvement
(n  142)
0.67 0.73 0.05 (0.10) 0.53 0.64 0.72 0.79 0.07 (0.23)
CSC
No improvement
(n  181)
0.64 0.64 0.003 (0.07) 0.04 0.04 0.68 0.64 0.04 (0.27)
Improvement
(n  86)
0.70 0.77 0.07 (0.11) 0.62 0.82 0.76 0.84 0.08 (0.24)
GroC
Large deterioration
(n  21)
0.60 0.54 0.07 (0.08) 0.86 0.83 0.60 0.31 0.28 (0.37)
Small deterioration
(n  66)
0.64 0.63 0.01 (0.08) 0.10 0.09 0.70 0.65 0.05 (0.25)
No change
(n  80)
0.66 0.68 0.01 (0.07) 0.19 0.16 0.69 0.69 0.003 (0.25)
Small improvement
(n  53)
0.68 0.70 0.03 (0.08) 0.35 0.32 0.76 0.79 0.03 (0.16)
Large improvement
(n  47)
0.70 0.80 0.10 (0.12) 0.89 1.24 0.73 0.88 0.15 (0.23)
SF-6D, Short-Form 6D utility derived by the UK tariff; EQ-5DUK, Euroqo
the Dutch tariff; DFDu, Depression-Free-Days derived utility derived f
9 points during follow-up); CSC, clinically significant change on the B
mean baseline utility score; T1, mean utility score at 12-month follow
standard deviations; SRM, standardized response mean; ES, effect siz
Bold indicates main outcomes.
Table 5 – ICC agreement and Spearman correlation betwee
(n = 267).
Utility change Utility ch
SF-6D EQ-5DUK
SF-6D 0.548
0.346 (0.236; 0.4
EQ-5DUK
EQ-5DNL
DFDu
SF-6D, Short-Form 6D utility derived by the UK tariff; EQ-5DUK, Euroqo
the Dutch tariff; DFDu, Depression Free Days derived utility derived f
All correlations and ICCs are significant at the 0.01 level.weremedium (0.397–0.449), correlations of the SF-6Dwith the EQ-
5DUK and EQ-5DNL were large (0.538–0.548), and the correlation
etween the EQ-5DUK and EQ-5DNL was very large (0.969). All ICC
alues showed poor agreement between the instruments (0.221–
.356), with exception of the strong agreement between the EQ-
DUK and EQ-5DNL (0.984).
Discussion
Main results
Based on the SRM and ES outcomes, the three utility measures:
SF-6D, EQ-5DUK, and EQ-5DNL, appeared to be responsive to
hanges in depression asmeasured by the BDI-II. As SRMand ES of
he improvement subgroups were highest in the SF-6D, the SF-6D
res with standard deviations ((SD)), standardized
p.
EQ-5DNL DFDu
ES T0 T1 (SD) SRM ES T0 T1 (SD) SRM ES
2.54 0.65 0.18 0.47 (0.38) 1.23 2.63 0.61 0.60 0.01 (0.03) 0.54 0.32
0.34 0.71 0.65 0.05 (0.23) 0.22 0.29 0.63 0.67 0.04 (0.08) 0.52 0.93
0.38 0.72 0.81 0.10 (0.21) 0.45 0.54 0.62 0.89 0.27 (0.13) 2.05 5.93
0.23 0.69 0.66 0.03 (0.25) 0.12 0.17 0.62 0.69 0.07 (0.10) 0.70 1.56
0.41 0.75 0.86 0.11 (0.22) 0.49 0.61 0.63 0.99 0.35 (0.06) 5.74 7.76
1.46 0.63 0.38 0.25 (0.35) 0.72 1.42 0.61 0.67 0.06 (0.10) 0.60 1.32
0.27 0.71 0.68 0.03 (0.23) 0.12 0.16 0.62 0.73 0.11 (0.14) 0.77 2.44
0.02 0.69 0.70 0.01 (0.25) 0.04 0.06 0.62 0.74 0.12 (0.14) 0.83 2.63
0.14 0.76 0.80 0.04 (0.16) 0.27 0.23 0.63 0.81 0.18 (0.15) 1.17 3.93
0.76 0.72 0.89 0.17 (0.21) 0.81 0.95 0.63 0.96 0.33 (0.10) 3.21 7.28
utility derived by the UK tariff; EQ-5DNL, Euroqol 5D utility derived by
the BDI-II; RC, reliable change on the BDI-II (i.e., a decrease of at least
(i.e., a follow-up score below 12); GRoC, global rating of change; T0,
(SD), mean utility change from baseline to 12-month follow-up with
ility change scores from baseline to 12 months follow-up
Spearman correlation ICC (95% CI)
EQ-5DNL DFDu
0.538
0.356 (0.247; 0.457)
0.403
0.226 (0.032; 0.437)
0.969
0.984 (0.972; 0.990)
0.397
0.221 (0.047; 0.372)
0.449
0.267 (0.082; 0.422)
utility derived by the UK tariff; EQ-5DNL, Euroqol 5D utility derived by
the BDI-II; ICC, intraclass coefficient; CI, confidence interval.e sco
grou
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DNL. The EQ-5DNL seemed to be better in capturing changes com-
aredwith the EQ-5DUK. Despite the large SRM and ES outcomes of
he DFDu changes, the direction of the SRM and ES often did not
orrespond with the change according to the anchors. That is, the
FDu SRM and ES nearly always provided moderate to large posi-
ive changes in utility, even for deterioration subgroups and sub-
roups that reported no change. Therefore, the DFDu seems less
uited to capturing negative quality of life changes. Additionally,
he ICC showedpoor agreement among the utility changes derived
rom the different instruments.
Responsiveness and MID of utility measures
This study showed the SF-6D, EQ-5DUK, and EQ-5DNL to be respon-
sive to changes in depression. This seems to be in contradiction
with earlier findings from the trial from which our data were de-
rived: The (cost-)effectiveness findings of our trial showed im-
provement in depression in the three treatment groups, but
merely no changes in SF-6D, EQ-5DUK, or EQ-5DNL quality of life
utility or QALY [4,24]. The BDI-II showed a mean 12-months im-
provement of 11.10, 9.77, and 10.47 points in score, respectively [4];
with RC improvement of 53.4%, 50.5%, and 61.4% of CCBT, TAU,
and combination treatment, respectively [45]. This contradiction
between the BDI-II outcomes versus the SF-6D, EQ-5DUK, and EQ-
DNL outcomes can be explained from two different perspectives:
either the overall change in depression of one treatment group
was not large enough to generate a substantial change in utility for
the respective treatment group, or theutility instrument—although
responsive—might be less able to capture smaller group changes in
depression severity. Further exploration on the relation between de-
pression severity and utilitymight focus on the question fromwhich
point on a utility instrument responds to a change in depression; for
example, how much change in depression severity results in a
change in utility, and whether or not this differs among depression
severity groups. It should be noted that we did not use the DFD
method to derive utilities or QALYs in the cost-effectiveness study.
The SF-6D responsiveness seems higher compared to the EQ-
5D. In accordance with the findings of Lamers et al. [46] the lower
standard deviations of the SF-6D utility change resulted in higher
SRM scores compared to the EQ-5D. This difference in standard
deviationsmight be a result of differences between the two instru-
ments’ valuations and descriptive system. Previous research indi-
cated thatmuch of the discrepancy between bothmeasures stems
from differences in the valuation of the health states [47]. And the
descriptive system of the SF-6D is more detailed toward depres-
sion changes than is the EQ-5D: Each of the five EQ-5D domains is
based on only one questionwith three answer options. And only the
EQ-5D domains anxiety/depression and usual activities can be con-
sidered directly influenced by changes in depression. The SF-6D is
derived from the SF-36 and includes six domains based on 11 ques-
tions with more than three answer options. Besides the mental
health domain, the questions used to derive the SF-6D explicitly
mention theaspect emotionalproblems in thesocial functioningand
role limitation domains, and include a domain on vitality. Only the
SF-6D domains physical functioning and pain focus specifically on
physical health.
The higher responsiveness of the EQ-5DNL as opposed to the
EQ-5DUKmight be explained by the tariff: The time-trade-off value
set of the UK tariff attaches lower values to the anxiety/depression
domain compared with the Dutch tariff [31,32,48]. Thus, a change
on the anxiety/depression domainwill havemore influence on the
EQ-5DNL than on the EQ-5DUK.
Our MID findings for the SF-6D and EQ-5D are rather close to
he 0.03 utility change, which is —based on the studies of Walters
nd Brazier [37,38]—often considered as a MID cut-off [see 49,50].
hese studies by Walters and Brazier on the anchor-based MID
sing the GRoC SF-36 item in various patient groups, found SF-6D shanges ranging from 0.010 to 0.097 [37,38], and EQ-5D changes
anging from0.011 to 0.14 to be important [37]. A recent study on
pinal cord injury using the same anchor, found a MID of 0.03 for
he SF-6D [51].
As argued by Brazier and Deverill [52], a larger ES does not
ecessarily imply a better utility instrument. Within economic
valuation, it is the change in preferences that matters. “ES or
linical changes do not reflect the importance of a change to pa-
ients. It is the sensitivity or responsiveness to changes in prefer-
nces that is required for economic evaluation [52].” From this
oint of view, we can argue the GRoC anchor to be more relevant
s opposed to the CSC or RC anchor for health-related quality of
ife, because the GRoC refers to a patient’s subjective experienced
hange in quality of life, subjective experience of if health status is
alued better, equal, or worse as opposed to health status 1 year
efore.
Although using general population preference-based utility
ariffs, the anchors used for calculating the responsiveness and
ID are not defined from a general population valuation. The re-
ults on responsiveness outcomes are calculated only using pa-
ient-based and distribution-based anchors. Other studies also
sed a clinician-based anchor to estimate responsiveness. The
ID is only based on a patient-based anchor, whereas also distri-
ution-basedmethods can be used. Asmentioned by Revicki et al.
23], however, the distribution-based approach will provide
hange scores that are clinically significant and meaningful, but
hese are not necessarily minimal. We therefore decided to limit
he MID analysis to the anchor-based approach using the GRoC
ased on the SF-36. But the use of the GRoC questions also has its
isadvantages. Recall bias of respondents can be expected in com-
aring today’s health with their health state 1 year ago [53]. Re-
earch also indicated that patients’ retrospective estimates of
ealth change are highly correlatedwith their present health state
54]. A patient’s valuation of quality of life might shift over time as
result of adaptation to the disorder. Experiencing changes in
ealth may change people’s internal standards, values, and/or
onceptualization of health-related quality of life [55]. Conse-
uently our data (not only theGRoC anchor, but also the utility and
DI-II data) might be subject to this response shift.
A limitation of this study is that some of the subgroups were
ather small (e.g., RC deterioration group, GRoC large deterioration
ubgroup). Moreover, the datawe usedwere trial data, whichwere
andomized into treatment groups. This means that the sub-
roups created on the GRoC, CSC, and RC anchors sometimes dif-
er with respect to baseline characteristics. Furthermore, we com-
ined the data of different treatment groups. It should however be
oted that the relation between depression change and utility
hange might be confounded by treatment type or by sociodemo-
raphic aspects. Therefore, we performed additional regression
nalyses to assess the potential influence of these aspects. These
dditional analyses (not shown in this article) indicate that the
elation between BDI-II change and utility change was not con-
ounded by treatment type or sociodemographic aspects.
Another point of attention is that this study indirectly assumes
concurrent relation between utility change from baseline to 12-
onth follow-up and depression change: the RC and CSC anchors
eflect the change in depression severity from baseline to 12-
onth follow-up. Because the utility instruments measure a pa-
ient’s subjective well-being, it can be expected that change in
uality of life is preceded by clinical change. It might take some
ime before a patient comes to realize how his changes in com-
laints affect his life in general. Therefore, not only the concurrent
elation between change in depression and utility, but also the
emporal relation between these changes could be of interest in
tudying responsiveness.
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Only one other study compared outcomes derived from the SF-6D,
EQ-5DNL, EQ-5DUK, and the DFD. In accordance with our findings,
onkers et al. [22] found a large agreement between the QALYs
ased on the EQ-5DNL and EQ-5DUK, and a poor agreement of the
QALY based on the DFD method with QALYs derived from either
the SF-6D, EQ-5DNL or EQ-5DUK. However studies of Jonkers et al.
22], Barton et al. [56], and Brazier et al. [57] mostly found better
greement between the SF-6D and EQ-5D compared to our study
i.e., ICC agreement of 0.47–0.53 between QALYs [22], Pearson cor-
elations about 0.7–0.8 between utilities [56], and/or ICC agree-
ent of 0.5–0.7 [56], respectively, 0.3–0.5 [57] between utilities).
his might be explained by our focus on depressive complaints,
hereas Barton et al. [56] and Brazier et al. [57] did not specifically
ocus onmental health complaints, and the study by Jonkers et al.
22] consisted of chronically ill elderly persons with co-occurring
epression. A study by Kontodimopoulos et al. [58] indeed found
n ICC value for depression of 0.441, whereas for most other clin-
cal (not specifically mental) conditions a somewhat higher ICC
greement of about 0.5was found. The finding of a poor agreement
etween different utility instruments implies that utilities derived
rom different instruments cannot be used interchangeably: Util-
ty changes derived from one instrument cannot be compared di-
ectly with utility changes derived from another utility instru-
ent.
Furthermore, although we focused on agreement in utility
hange, previous studies assessed agreement in utility [56–58] or
ALY [22]. Our reason for using utility change instead of QALYwas
hat we were interested in measuring if the instruments are re-
ponsive (i.e., can show changes). In our study, calculating the
ALY during the 1-year follow-up period would mean that we
djusted the length of the follow-up period by the utility value of
oth the baseline and follow-up period. The inclusion of the base-
ine utility value in the QALY would mean that it shows less
hange than looking at the difference between the follow-up and
he baseline utility. Moreover, an advantage of the QALY is that it
imultaneously combines morbidity and mortality [3]. But in our
tudy there was no mortality.
Limitations of the DFDu instrument
Based on our outcomes, the DFD seems not suited for deriving
utility (and subsequently calculating QALY) in depression. The
positive and large SRM and ES of the DFDu might be explained by
the range of the DFD. TheDFD attaches utilityweights in the range
of 0.6 to 1.0 to the BDI-II score of greater than 21 and less than 9,
respectively [8]. At baseline, the required BDI score of our trial
articipants was at least 16, whereas the actual mean BDI score
as 27.7. In total 78% of all trial participants had a baseline score
bove 21 (DFDu of 0.6), meaning that they could not show a de-
rease in DFD-derived utility during the follow-up period. The
FDu of this 78% could only remain constant at 0.6 or improve
oward 1.0, whereas an increase in depression severity (BDI-II)
ould not be projected in their DFDu. This also resulted in small
tandard deviations of the baseline DFDu and of change in DFDu,
eading to very large SRMs and ESs. The DFDu does give high cor-
elations with the BDI-II, and a high predictive power from the
DI-II. But these findings are less than surprising because the
FDu is derived from the BDI-II.
Although we do not recommend the DFDmethod based on our
outcomes, this conclusion must be drawn with caution because
we only used onemanner to calculate the DFDu based on only one
data set. Broadening the ranges of the BDI-II and utilities in the
calculation of the DFDu might overcome some of the DFDu limi-
tations. Some economic evaluation studies adopted themethod of
Lave et al. [9] to calculate DFD-based QALYs [10,12]. However,
other studies deriving utilities and/or QALYs from the DFD-method have used a different range then the 0.6 to 1.0 utility,
varied the BDI-II or Hamilton Rating Scale-Depression score to
attach the minimal and maximal utility, and/or used another de-
pression questionnaire instead of the BDI-II or Hamilton Rating
Scale-Depression [11,13–21]. Thus, different studies used different
methods to calculate the utility and/or QALY through the DFD
method. These variations might improve the DFD method and
imply differences in the utility outcomes. However, the compara-
bility of the DFD-derived quality of life outcomes with the out-
comes of generic utility instruments may still cause problems be-
cause the DFD method attaches utility weights to depression
severity outcome alone. The DFD-derived QALY or utility thus
might not take into account possible changes in other health-
related quality of life aspects resulting through side effects of
treatment or comorbidity of depression.
Conclusions
Based on our results, the SF-6D, EQ-5DUK, and EQ-5DNL are respon-
ive to changes related to depression severity and health status,
nd thus seem adequate for estimating utility in depression treat-
ent. We do not recommend the use of the DFD method. For
espondents reporting no change or a worsening of their health
tatus or depression severity according to the CSC or GRoC anchor,
he SRM and ES of the DFDu even reported an improvement in
uality of life. Because the agreement between the generic utility
hanges (i.e., SF-6D, EQ-5DUK, and EQ-5DNL) and the DFDu changes
s well as between the SF-6D and EQ-5D was poor, the utilities
rom these instruments do not seem comparable.
Source of financial support: This study was an addition to a
rial financed by ZonMw (Netherlands Organisation for Health Re-
earch and Development; project No. 945-04-417), research insti-
ute EPP and research institute CAPHRI. Municipalities Eijsden,
eerssen, Sittard-Geleen, Valkenburg, and Maastricht sponsored
he trial study. The study sponsors had no role in the design of the
tudy; in the collection, analysis, and interpretation of the data; in
hewriting of the report; or in the decision to submit the article for
ublication.
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